Feasibility of adjuvant chemotherapy for breast cancer patients.
Feasibility of adjuvant chemotherapy for breast cancer patients.
复制标题
乳腺癌患者辅助化疗的可行性。
DOI：
--
复制
发表时间：
1997
影响因子：
2.4
通讯作者：
S. Imoto
中科院分区：
文献类型：
--
作者：
S. Imoto
为了评估辅助化疗的可行性，我们分析了日本女性原发性乳腺癌化疗的毒性。自国家癌症中心医院东院开业以来，1992年6月至1995年12月期间，已有180名女性乳腺癌患者在手术治疗后接受了辅助化疗或化学激素治疗。在对预后和辅助治疗知情同意的基础上，大多数患者决定自己选择细胞毒化疗的类型。辅助化疗包括口服氟嘧啶化合物 (OFP)、环磷酰胺 + 阿霉素 +/- 5-氟尿嘧啶 [CA(F)] 或环磷酰胺 + 甲氨蝶呤 + 5-氟尿嘧啶 (CMF)。使用日本临床肿瘤学组（JCOG）的毒性分级标准确定毒性。 66 名患者接受了 OFP，59 名患者接受了 CA(F)，其余 55 名患者接受了 CMF。使用CA(F)或CMF治疗的患者的白细胞和中性粒细胞的毒性分级显着高于使用OFP治疗的患者。在恶心/呕吐和脱发的毒性方面也发现了类似的结果。三组患者血红蛋白、谷草酰乙酸转氨酶/谷氨酸丙酮酸转氨酶（GOT/GPT）、口腔炎/胃炎的毒性分级无统计学差异。有趣的是，接受 OFP 的患者中被迫停止化疗的患者数量高于接受 CA(F) 或 CMF 的患者。 CA(F) 或 CMF 的细胞毒性化疗比 OFP 产生更大的毒性，但从抗癌化疗的毒性角度来看，在日本乳腺癌患者的辅助治疗中是耐受的且可行的。
To evaluate the feasibility of adjuvant chemotherapy, we analyzed the toxicities of chemotherapy for primary breast cancer in Japanese women. Since the opening of the National Cancer Center Hospital East, 180 female breast cancer patients have received adjuvant chemotherapy or chemo-hormonal therapy following surgical treatment between June 1992 and December 1995. On the basis of informed consent about prognosis and adjuvant therapy, most patients decided to choose the type of cytotoxic chemotherapy themselves. Adjuvant chemotherapy consisted of oral fluoropyrimidine compounds (OFP), cyclophosphamide + adriamycin +/- 5-fluorouracil [CA(F)] or cyclophosphamide + methotrexate + 5-fluorouracil (CMF). Toxicity was determined using the Toxicity Grading Criteria of the Japan Clinical Oncology Group (JCOG). Sixty-six patients received OFP, 59 CA(F) and the rest 55 CMF. The toxicity grading of leukocytes and neutrophils was significantly higher in patients treated with CA(F) or CMF than in those treated with OFP. Similar results were also seen relating to the toxicity of nausea/vomiting and alopecia. There was no statistical difference in the toxicity grading of hemoglobin, glutamic oxaloacetic transaminase/glutamic pyruvic transaminase (GOT/GPT) and stomatitis/ gastritis between the three groups of patients. Interestingly, the number of patients that were forced to discontinue chemotherapy was higher in those receiving OFP than in those receiving CA(F) or CMF. Cytotoxic chemotherapy of CA(F) or CMF results in greater toxicity than OFP, but is tolerated and feasible in the adjuvant setting used in Japanese breast cancer patients from the viewpoint of toxicities by anticancer chemotherapy.
乳腺癌辅助化疗期间的急性毒性：国家外科辅助乳腺和肠道项目 (NSABP) 来自 1717 名接受单一和多种药物治疗的患者的经验。
DOI：
--
发表时间：
1981
期刊：
Cancer treatment reports
影响因子：
--
作者：
Glass,A;Wieand,HS;Fisher,B;Redmond,C;Lerner,H;Wolter,J;Shibata,H;Plotkin,D;Foster,R;Margolese,R;Wolmark,N
通讯作者：
Wolmark,N